Mesoblast (NASDAQ:MESO) Shares Gap Up – What’s Next?

Shares of Mesoblast Limited (NASDAQ:MESO) gapped up before the market opened on Monday . The stock had previously closed at $15.44, but opened at $16.21. Mesoblast shares last traded at $16.27, with a volume of 96,815 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Mesoblast Stock Up 5.3%

The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -58.04 and a beta of 2.08. The business has a fifty day moving average price of $14.60 and a two-hundred day moving average price of $15.86.

Institutional Trading of Mesoblast

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Mesoblast during the fourth quarter worth about $32,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Mesoblast by 30.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after purchasing an additional 558 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Mesoblast by 55.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after purchasing an additional 1,012 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Mesoblast during the 2nd quarter worth approximately $86,000. Finally, NBC Securities Inc. acquired a new stake in shares of Mesoblast during the 4th quarter worth approximately $89,000. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.